+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 3 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are investigating new treatments for neovascular age-related macular degeneration NVAMD, a condition that affects the eye and vision. This trial aims to compare a new medicine called tiespectus also known as MK-8748 or EYE201 with the standard treatment aflibercept to see if tiespectus works as well for people with NVAMD. The study is a randomized, double-masked, pivotal phase 23 trial focusing on treatment effectiveness and safety. Participants will be assigned to one of three groups one receiving a low dose of tiespectus, another receiving a high dose of tiespectus, and a third group receiving aflibercept. In the tiespectus groups, participants will get three initial injections every four weeks, followed by injections every eight weeks until week 48. After week 48, treatment intervals will be personalized based on individual responses, continuing up to week 92. The aflibercept group also receives three initial injections followed by injections every eight weeks until week 92. Throughout the study, participants will have their vision assessed using a standard eye chart to measure changes in best-corrected visual acuity BCVA from the start through one year. Additional measures include eye imaging to assess retinal thickness and monitoring for any side effects or adverse events up to approximately 96 weeks. The trial will last until June 2028, with ongoing monitoring and follow-up visits to evaluate the safety and effectiveness of the treatments.

Age: 50Years +All GendersPhase 2Phase 3
132 locations
E

Actively Recruiting

Researchers are investigating new treatments for diabetic macular edema DME, a condition that can cause vision loss. This trial aims to compare the effects of a new medicine called MK-8748 with the current standard treatment, aflibercept, to see if MK-8748 works as well. The study focuses on adults with type 1 or type 2 diabetes who have vision decrease due to DME. Participants will be randomly assigned to one of three groups two groups receive different doses of MK-8748 via injections into the eye, starting with five doses every 4 weeks, then every 8 weeks until week 48, followed by treatment intervals based on individual response up to week 100. The third group receives aflibercept injections on a similar schedule for up to 100 weeks. The study is double-masked and multicenter, designed to carefully compare these treatments. During the trial, participants will have regular eye examinations, including measurements of visual acuity and retinal thickness, along with imaging tests such as optical coherence tomography and fluorescein angiography. Researchers will monitor changes in vision and eye condition over one to two years, assess treatment safety, and track adverse events and drug levels. The main outcome measured is the change in best-corrected visual acuity after one year of treatment.

Age: 18Years +All GendersPhase 3
35 locations
R

Actively Recruiting

Researchers are evaluating the drug ADX-038 in participants aged 60 years and older who have geographic atrophy GA secondary to age-related macular degeneration AMD. This Phase 2, randomized, masked, placebo-controlled study aims to compare the effects of ADX-038 with a placebo on preserving the ellipsoid zone EZ layer in the eye over 12 months. The trial will also assess the safety, pharmacokinetics, and pharmacodynamics of ADX-038. Participants will receive either subcutaneous injections of ADX-038, a siRNA duplex oligonucleotide, or a saline placebo. The study uses a parallel design where participants are randomly assigned to one of these two groups. The treatment is administered over a 12-month period, during which the impact on eye structure and function will be closely monitored. Throughout the study, participants will attend clinic visits for assessments, including high-quality fundus imaging and other study-related procedures. They must complete meningococcal and pneumococcal vaccinations as required by the protocol. Researchers will monitor the preservation of the EZ layer as the primary outcome to evaluate treatment effect, alongside safety and drug behavior in the body. The total study duration extends until August 2030, with primary outcome results expected by February 2030.

Age: 60Years +All GendersPhase 2
83 locations